Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma ... in the Division of Oncology at Huntsman Cancer Institute of the University of Utah in Salt Lake City, spoke with CURE® about the ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application of VS-7375, its oral KRAS G12D inhibitor. An oral KRAS G12D inhibitor ...

The company has returned to Redx Pharma’s well, this time paying $10 million upfront for a KRAS program that includes the much-hyped G12D space. Initially Jazz and Redx will collaborate to ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V ... Cancer Institute in Salt Lake City, Utah.

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

Mutation of the Ras gene causes signaling dysregulation, which can promote tumor development and growth. KRAS mutations, especially G12D, G12V and G12C, are highly prevalent in pancreatic, colorectal ...

Verastem Oncology has announced the dosing of the first patient with GFH375/VS-7375, a potent and selective oral KRAS G12D (ON/OFF) inhibitor, as part of a Phase I/II clinical trial in China.

KRAS mutations, especially G12D, G12V, and G12C, are highly prevalent in pancreatic, colorectal, and lung cancers. First-generation KRAS inhibitors have demonstrated clinical benefit, but their ...

SIL-204, with an extended-release formulation, demonstrated significant tumor reduction in KRAS G12D-mutated pancreatic cancer cell lines. Silexion plans to initiate Phase 2/3 trials for SIL-204 ...